Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Earnings Conference call for Q4 FY2302-05-2023
02-05-2023
Rossari Biotech Results Earnings Call for Q4FY23
Conference Call with Rossari Biotech Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.02-05-2023
Q4FY23 Quarterly & FY23 Annual Result Announced for Rossari Biotech Ltd.
Specialty Chemicals company Rossari Biotech announced Q4FY23 & FY23 results: Consolidated Q4FY23 vs Q3FY23: Revenue from operations stood at Rs 406.5 crore as against Rs 389.3 crore EBITDA at Rs 54.6 crore as against Rs 54.2 crore; EBITDA margin at 13.4% as against 13.9% PAT stood at Rs 29.0 crore as against Rs 25.7 crore EPS (Diluted) stood at Rs 5.2 as against Rs 4.6 Consolidated FY23 vs FY22: Revenue from operations stood at Rs 1,655.9 crore as against Rs 1,483.0 crore EBITDA at Rs 223.0 crore as against Rs 183.4 crore; EBITDA margin at 13.5% as against 12.5% PAT stood at Rs 107.3 crore as against Rs 97.7 crore EPS (Diluted) stood at Rs 19.4 as against Rs 17.7 Standalone Q4FY23 vs Q3FY23: Revenue from operations stood at Rs 263.6 crore as against Rs 236.9 crore EBITDA at Rs 35.8 crore as against Rs 31.9 crore; EBITDA margin at 13.6% as against 13.5% PAT stood at Rs 23.1 crore as against Rs 17.5 crore EPS (Diluted) stood at Rs 4.2 as against Rs 3.2 Commenting on the performance, in a joint statement, Edward Menezes, Promoter & Executive Chairman, and Sunil Chari, Promoter & Managing Director, said “We are pleased to close the year on a steady note, with revenues increasing by 4.4% on a Q-o-Q basis. While we faced several macro and operational challenges during the year, we believe, we have effectively addressed them and are now positioned to deliver consistent growth going forward. With a focus on cost management, better margin products, and moderation in raw material costs, we were able to improve our Gross and EBITDA margins throughout the year, reaching 29.3% and 13.5%, respectively, as at year ended FY23. Both our acquisitions Unitop Chemicals Private Limited and Tristar Intermediates Private Limited have added significant value to our portfolio by expanding our market reach, R&D; capabilities, operations, business development, and product offerings. We have already experienced significant benefits from the synergies between these companies and our existing business units, impact of which will be further visible over the next few years. The specialty chemicals industry in India is poised for significant growth in the coming years, driven by as increasing demand for specialized chemicals in various end-use industries and the shift towards sustainability. Overall, our strong financial position, strengthened product portfolio, fungible manufacturing facilities, our focus on constant innovation and green solutions, and other inherent strengths, provide a solid foundation for us to create a healthier and more sustainable future. We remain committed to delivering long-term value to our stakeholders while maintaining our market position as a top provider of intelligent and sustainable solutions. As we continue to evolve and innovate, we remain optimistic about our ability to capitalize on emerging opportunities in the market. Overall our financial position remains strong. Even after undertaking organic and inorganic expansion over the last few years, our balance sheet profile is healthy. As on March 31, 2023, we continue to be net cash positive with net cash of Rs 77 crores." Result PDF02-05-2023
Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Newspaper Publication
News Paper Publication of extracts of Consolidated Audited Financial Results for the Quarter and Financial Year ended March 31, 2023.01-05-2023
Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Rossari Biotech Limited has informed the Exchange regarding a Press Release dated April 29, 2023, titled "Rossari Biotech announces Q4 & FY 23 results"30-04-2023
Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Investor Presentation
Intimation of Q4 & FY23 Earnings Presentation.30-04-2023
Rossari Biotech Ltd - 543213 - Grant Of Options Under Rossari Employee Stock Option Plan - 2019.
Rossari Biotech Limited has informed the Exchange regarding Grant of 15800 Options.30-04-2023
Rossari Biotech Ltd - 543213 - Disclosure On Related Party Transactions On Consolidated Basis For The Half Year Ended March 31, 2023.
Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the disclosure of Related Party Transactions on a consolidated basis, in the prescribed format, for the half year ended March 31, 2023.29-04-2023
Rossari Biotech Ltd - 543213 - Intimation Under Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015.
Contact details of Key Managerial Personnel who are severally authorised to determine materiality of an event or information and make disclosures to Stock Exchange pursuant to Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.29-04-2023
Rossari Biotech Ltd - 543213 - Announcement Under Regulation 30 Of Listing Regulations.
Rossari Biotech Limited has informed the Exchange regarding: 1. Appointment of Ms. Aparna Sharma as Additional Director designated as Non- Executive Independent Director of the Company with effect from April 29, 2023. 2. Change in Key Managerial Personnel (Chief Financial Officer) of the Company.29-04-2023